Xenetic Biosciences

Historical price data

Xenetic Biosciences is a lean, platform-focused biotech advancing its systemic DNase I candidate as an adjunctive therapy to re-sensitize tumors to existing treatments. The company's strategy targets a novel mechanism of action—degrading neutrophil extracellular traps (NETs)—to address chemotherapy and immunotherapy resistance in solid tumors. With its lead program poised for clinical entry and a leadership team featuring deep oncology and business development expertise, Xenetic aims to create value through platform validation and strategic partnerships.

Proprietary DNase I Oncology Platform designed to degrade neutrophil extracellular traps (NETs) in the tumor microenvironment to overcome therapy resistance and inhibit metastasis.

The direct competitive landscape for NET-targeting therapies is nascent, with a few private companies and academic groups exploring the space. Xenetic's key competition is the broader challenge of demonstrating meaningful efficacy over existing standard-of-care regimens. Its first-mover potential in systemic DNase therapy is a distinct but unproven advantage.